EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 1010 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR This Amazing Woman Can Smell Alzheimer’s, Parkinson’s, and Cancer Years Before... March 22, 2019 Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers February 3, 2026 DNA from Ancient Viruses Helps Many Cancers Grow September 6, 2024 Addressing Cancer Pain with Complementary Methods (Part 2) April 10, 2023 Load more HOT NEWS The stories behind Teenage and Young Adult Cancer Awareness Month Man Offers Free Lawn Mowing Service To Elderly And Veterans A real Eureka moment for translation Speaking with One Cancer Voice for cancer patients in England
